3rd Edition of International Conference on
Neurology and Brain Disorders
- June 24-26, 2019
- Paris, France
Background: Subjective memory complaints (SMC) are often detected in the elderly. APOEɛ4 genotype has been identified as the most important risk factor for late onset Alzheimer Disease (AD). We aimed to evaluate temporal change of Tau and Amyloid Beta (Aβ) in SMC with APOE-ε4 carriers (C) and non-carriers (NC) based on cognitive tests.
Method: In order to find cognitive changes from baseline to 1 year follow up of AD patients, Assessment Scale (ADAS)-13 scores were evaluated according to APOE-ɛ4 status in SMC cases from Alzheimer’s Disease Neuroimaging Initiative (ADNI) data. SMC cases were divided into two groups as NC and C according to APOE-ε4 genotypes. Phosphorylated Tau (PTau) and Aβ were compared among the groups.
Results: Total 87 SMC cases (n:33 C, 54 NC, female/male: %51/49, mean age of NC group was 72± 5.5 and C group was 70±5.2 years) were enrolled to the study from ADNI. PTau levels were 28.5± 12,35.8± 18, 20.1± 6, 20.8± 7 pg/ml in C and NC group at baseline and 24 months later, respectively. In C group, PTau levels were significantly high since the begining. Aβ levels were 961± 378, 799± 274, 1180± 347, 1097.8± 355 pg/ml in C and NC group at baseline and 24 months later respectively. In C group, Aβ levels were significantly low since the beginning. There were no significant difference between two groups of ADAS-13 scores at the beginning or 24 months later.
Conclusion: APOEɛ4 carriage may be associated with cognitive impairment in SMC as well as AD patients despite the accumulation of Tau and Aβ
where cognitive dysfunction cannot be measured by objective tests. Long-term follow-up studies are needed.